Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: A combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment

Journal of Clinical Oncology

Volumn 16, Issue 1, 1998, Pages 261-268

  Leibovitch, Ilan ^a   Foster, Richard S ^a   Kopecky, Kenyon K ^a   Albers, Peter ^a   Ulbright, Thomas M ^a   Donohue, John P ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; EMBRYONAL CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PRIORITY JOURNAL; TESTIS CANCER;

EID: 0031982504     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.1.261     Document Type: Article

References (13)

1. Baniel J, Foster RS, Rowland RG, et al: Complications of retroperitoneal lymph node dissection. J Urol 152:424-427, 1994
2. Donohue JP, Thornhill JA, Foster RS, et al: Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965 to 1989): Modifications of technique and impact on ejaculation. J Urol 149:237-243, 1993
3. Donohue JP, Thornhill JA, Foster RS, et al: Primary retroperitoneal lymph node dissection in clinical stage A nonseminomatous germ cell testis cancer. BrJ Urol 71:326-335, 1993
4. Read G, Stenning SP, Cullen MH, et al: Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 10:1762-1768, 1992
5. Donohue JP, Thornhill JA, Foster RS, et al: Stage I nonseminomatous germ cell testicular cancer management options and risk-benefit considerations. World J Urol 12:170-177, 1994
6. Donohue JP: Unsolved problems in testis cancer. Eur Urol 23:57-59, 1993 (suppl)
7. De Riese WTW, De Riese C, Ulbright TM, et al: Flow cytometric and quantitive histologic parameters as prognostic indicators for occult retroperitoneal disease in clinical stage 1 nonseminomatous testicular germ cell tumors. Int J Cancer 57:628-633, 1994
8. Moul JW, McCarthy WF, Fernandez EB, et al: Percentage of embryonal carcinoma and of vascular invasion predicts pathological stage in clinical stage 1 nonseminomatous testicular cancer. Cancer Res 54:362-364, 1994
9. Moul JW, Foley JP, Hitchcock CL, et al: Flow cytometric and quantitive histological parameters to predict occult disease in clinical stage I nonseminomatous testicular germ cell tumors. J Urol 150:879-883, 1993
10. De Riese WTW, Albers P, Walker EB, et al: Predictive parameters of biologic behavior of early stage nonseminomatous testicular germ cell tumors. Cancer 74:1335-1341, 1994
11. Albers P, Miller GA, Orazi A, et al: Immunohistochemical assessment of tumor proliferation and volume of embryonal carcinoma identify patients with clinical stage A nonseminomatous testicular germ cell tumor at low risk for occult metastasis. Cancer 75:844-850, 1995
12. Leibovitch I, Foster RS, Kopecky KK, et al: Improved accuracy of computerized tomography based clinical staging in low stage nonseminomatous germ cell cancer using size criteria of retroperitoneal lymph nodes. J Urol 154:1759-1763, 1995
13. Hosmer DW Jr, Lemeshow S: Assessing the fit of the model, in Applied Logistic Regression. New York, NY, Wiley, pp 135-175